MDG1 Stock Overview
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Medigene AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.52 |
52 Week High | €2.90 |
52 Week Low | €1.31 |
Beta | 0.85 |
1 Month Change | -29.21% |
3 Month Change | -2.26% |
1 Year Change | -9.82% |
3 Year Change | -61.74% |
5 Year Change | -81.95% |
Change since IPO | -99.45% |
Recent News & Updates
Recent updates
Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation
Jan 03The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business
Aug 12Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%
Aug 10We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely
Mar 24Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation
Nov 29This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO
Jun 17We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate
Mar 29How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 16How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?
Dec 23Shareholder Returns
MDG1 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 9.8% | -1.5% | 1.9% |
1Y | -9.8% | -23.6% | 4.6% |
Return vs Industry: MDG1 exceeded the German Biotechs industry which returned -21.9% over the past year.
Return vs Market: MDG1 underperformed the German Market which returned 4.2% over the past year.
Price Volatility
MDG1 volatility | |
---|---|
MDG1 Average Weekly Movement | 13.6% |
Biotechs Industry Average Movement | 5.3% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MDG1's share price has been volatile over the past 3 months.
Volatility Over Time: MDG1's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 76 | Selwyn Ho | www.medigene.com |
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Medigene AG Fundamentals Summary
MDG1 fundamental statistics | |
---|---|
Market cap | €37.21m |
Earnings (TTM) | -€16.18m |
Revenue (TTM) | €6.03m |
6.2x
P/S Ratio-2.3x
P/E RatioIs MDG1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MDG1 income statement (TTM) | |
---|---|
Revenue | €6.03m |
Cost of Revenue | €1.64m |
Gross Profit | €4.39m |
Other Expenses | €20.57m |
Earnings | -€16.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.66 |
Gross Margin | 72.77% |
Net Profit Margin | -268.10% |
Debt/Equity Ratio | 0% |
How did MDG1 perform over the long term?
See historical performance and comparison